Sarbattama Sen

Sarbattama Sen

Auto-generated profile, based on publicly available information

Sarbattama Sen

Department of Pediatric Newborn Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2017 in Pediatric Obesity
Verified
Journal Article
Closed access
PDF file
SSS. Sen
S. Sen
SRS. L. Rifas‐Shiman
S. L. Rifas‐Shiman
NSNitin Shivappa
Nitin Shivappa
MWM. D. Wirth
M. D. Wirth
JHJ. R. Hebert
J. R. Hebert
EOE. Oken
E. Oken

18 June 2019 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
DTDaria Turner
Daria Turner
CMCarmen Monthé-Drèze
Carmen Monthé-Drèze
SCSara Cherkerzian
Sara Cherkerzian
KGKatherine Gregory
Katherine Gregory
SSSarbattama Sen
Sarbattama Sen

9 February 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
CMCarmen Monthe-Dreze
Carmen Monthe-Dreze
SSSarbattama Sen
Sarbattama Sen
SMSylvie Hauguel-de Mouzon
Sylvie Hauguel-de Mouzon
Patrick M. CatalanoPatrick M. Catalano
Patrick M. Catalano
Maternal obesity, a state of chronic low-grade metabolic inflammation, is a growing health burden associated with offspring adiposity, abnormal fetal growth and prematurity, which are all linked to adverse offspring cardiometabolic health. Higher intake of anti-inflammatory omega-3 (n-3) polyunsaturated fatty acids (PUFA) in pregnancy has been associated with lower adiposity, higher birthweight and longer gestation. However, the effects of n-3 supplementation specifically in pregnant women with overweight and obesity (OWOB) have not been explored. We conducted a pilot double-blind randomized controlled trial of 72 pregnant women with first trimester body mass index (BMI) ≥ 25 kg/m2 to explore preliminary efficacy of n-3 supplementation. Participants were randomized to daily DHA plus EPA (2 g/d) or placebo (wheat germ oil) from 10–16 weeks gestation to delivery. Neonatal body composition, fetal growth and length of gestation were assessed. For the 48 dyads with outcome data, median (IQR) maternal BMI was 30.2 (28.2, 35.4) kg/m2. In sex-adjusted analyses, n-3 supplementation was associated with higher neonatal fat-free mass (β: 218 g; 95% CI 49, 387) but not with % body fat or fat mass. Birthweight for gestational age z-score (−0.17 ± 0.67 vs. −0.61 ± 0.61 SD unit, p = 0.02) was higher, and gestation longer (40 (38.5, 40.1) vs. 39 (38, 39.4) weeks, p = 0.02), in the treatment vs. placebo group. Supplementation with n-3 PUFA in women with OWOB led to higher lean mass accrual at birth as well as improved fetal growth and longer gestation. Larger well-powered trials of n-3 PUFA supplementation specifically in pregnant women with OWOB should be conducted to confirm these findings and explore the long-term impact on offspring obesity and cardiometabolic health.

4 December 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
CMCarmen Monthe-Dreze
Carmen Monthe-Dreze
APAnnie Penfield-Cyr
Annie Penfield-Cyr
MSMarcela C. Smid
Marcela C. Smid
SSSarbattama Sen
Sarbattama Sen
Maternal obesity is associated with adverse offspring outcomes. Inflammation and deficiency of anti-inflammatory nutrients like omega(n)-3 polyunsaturated fatty acids (PUFA) may contribute to these associations. Fetal supply of n-3 PUFA is dependent on maternal levels and studies have suggested that improved offspring outcomes are associated with higher maternal intake. However, little is known about how maternal obesity affects the response to n-3 supplementation during pregnancy. We sought to determine (1) the associations of obesity with PUFA concentrations and (2) if the systemic response to n-3 supplementation differs by body mass index (BMI). This was a secondary analysis of 556 participants (46% lean, 28% obese) in the Maternal-Fetal Medicine Units Network trial of n-3 (Docosahexaenoic acid (DHA) + Eicosapentaenoic acid (EPA)) supplementation, in which participants had 2g/day of n-3 (n = 278) or placebo (n = 278) from 19 to 22 weeks until delivery. At baseline, obese women had higher plasma n-6 arachidonic acid concentrations (β: 0.96% total fatty acids; 95% Confidence Interval (CI): 0.13, 1.79) and n-6/n-3 ratio (β: 0.26 unit; 95% CI: 0.05, 0.48) compared to lean women. In the adjusted analysis, women in all BMI groups had higher n-3 concentrations following supplementation, although obese women had attenuated changes (β = −2.04%, CI: −3.19, −0.90, interaction p = 0.000) compared to lean women, resulting in a 50% difference in the effect size. Similarly, obese women also had an attenuated reduction (β = 0.94 units, CI: 0.40, 1.47, interaction p = 0.046) in the n-6/n-3 ratio (marker of inflammatory status), which was 65% lower compared to lean women. Obesity is associated with higher inflammation and with an attenuated response to n-3 supplementation in pregnancy.

2 December 2020 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
VGVictoria R. Gill
Victoria R. Gill
HLHelen G. Liley
Helen G. Liley
CECarmina Erdei
Carmina Erdei
SSSarbattama Sen
Sarbattama Sen
RDRuth Davidge
Ruth Davidge
SBSamudragupta Bora
Samudragupta Bora

26 October 2017 in Breastfeeding Medicine
Verified
Journal Article
Closed access
SSSarbattama Sen
Sarbattama Sen
CBCharis Benjamin
Charis Benjamin
JRJennifer Riley
Jennifer Riley
AHAbigail Heleba
Abigail Heleba
KDKaitlin Drouin
Kaitlin Drouin
MBMandy Brown Belfort
Mandy Brown Belfort
Background: Banked donor milk (BDM) has historically been used as an alternative to formula for preterm infants. Recently, BDM has been endorsed by two national organizations for use in healthy infants. We sought to quantify utilization trends and characteristics of mothers and their healthy newborns who received BDM during their postpartum stay between 2013 and 2016 at a single academic medical center. Materials and Methods: In this observational study, we used a clinical log to identify all infants who received BDM in the well-baby nursery between July 2013 and June 2016. From this log, we abstracted data on the numbers of babies who received BDM, the quantity of BDM provided, and indications for usage. We also collected clinical data from the medical records of a subset of corresponding mothers and infants. Results: BDM utilization increased over time in healthy infants, with 0.04% of infants before July 2014 receiving BDM compared with 4.7% in July 2015 to June 2016. During the same periods, the number of bottles provided per infant also increased, from 0.6 bottles per infant to 4.6 bottles per infant. The most common indications for providing BDM were parent/caregiver request (19%) and excessive weight loss/dehydration (17%). Conclusion: At our center, the use of BDM for healthy infants increased substantially over the study period. More research is urgently needed to understand the repercussions of this practice on resource utilization as well as short- and long-term breastfeeding and health outcomes.